Novartis's FSHD drug (del-brax) meets Phase I/II biomarker endpoints, advancing potential first-in-class treatment.

summarizeSummary

Novartis's investigational drug del-brax achieved positive Phase I/II results for FSHD, demonstrating potential as the first disease-modifying treatment for the rare neuromuscular disorder.

check_boxKey Events

• Positive Phase I/II Results

  Delpacibart braxlosiran (del-brax) met primary and key secondary biomarker endpoints in the FORTITUDE Phase I/II study for facioscapulohumeral muscular dystrophy (FSHD), showing reductions in KHDC1L and creatine kinase levels.

• Potential First-in-Class Treatment

  Del-brax indicates potential to become the first disease-modifying treatment for FSHD, a progressive and irreversible neuromuscular disease affecting 45-87k people in the US and EU, which currently has no approved therapies.

• Advancing Regulatory Pathway

  Novartis plans to engage global regulatory authorities on the Phase I/II data. Del-brax has FDA Orphan Drug and Fast Track designations, and a Phase III study is currently enrolling.

• Validation of Strategic Acquisition

  Del-brax is a key asset acquired through the Avidity Biosciences acquisition, completed in February 2026, and these positive results validate that strategic investment.

auto_awesomeAnalysis

Novartis announced positive Phase I/II results for del-brax, a potential first-in-class treatment for facioscapulohumeral muscular dystrophy (FSHD). The study met its primary and key secondary biomarker endpoints, showing strong target engagement and reduced muscle damage. This validates a key asset from the recent Avidity Biosciences acquisition and positions del-brax, which has Orphan Drug and Fast Track designations, for continued Phase III development in a disease with no approved therapies.